Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.28
NVS's Cash-to-Debt is ranked lower than
82% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. NVS: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
NVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.05 Max: 3.39
Current: 0.28
0.18
3.39
Equity-to-Asset 0.52
NVS's Equity-to-Asset is ranked lower than
67% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NVS: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
NVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.52
0.51
0.65
Debt-to-Equity 0.44
NVS's Debt-to-Equity is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. NVS: 0.44 )
Ranked among companies with meaningful Debt-to-Equity only.
NVS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12  Med: 0.26 Max: 0.48
Current: 0.44
0.12
0.48
Debt-to-EBITDA 2.32
NVS's Debt-to-EBITDA is ranked lower than
59% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. NVS: 2.32 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.55  Med: 1.61 Max: 2.79
Current: 2.32
0.55
2.79
Interest Coverage 11.07
NVS's Interest Coverage is ranked lower than
72% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. NVS: 11.07 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 11.07  Med: 16.22 Max: 30.91
Current: 11.07
11.07
30.91
Piotroski F-Score: 6
Altman Z-Score: 2.45
Beneish M-Score: -2.80
WACC vs ROIC
5.93%
7.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 16.05
NVS's Operating Margin % is ranked higher than
74% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. NVS: 16.05 )
Ranked among companies with meaningful Operating Margin % only.
NVS' s Operating Margin % Range Over the Past 10 Years
Min: 16.05  Med: 20.76 Max: 22.35
Current: 16.05
16.05
22.35
Net Margin % 13.23
NVS's Net Margin % is ranked higher than
74% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. NVS: 13.23 )
Ranked among companies with meaningful Net Margin % only.
NVS' s Net Margin % Range Over the Past 10 Years
Min: 13.23  Med: 18.81 Max: 35.29
Current: 13.23
13.23
35.29
ROE % 9.09
NVS's ROE % is ranked higher than
58% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. NVS: 9.09 )
Ranked among companies with meaningful ROE % only.
NVS' s ROE % Range Over the Past 10 Years
Min: 8.95  Med: 14.79 Max: 25.73
Current: 9.09
8.95
25.73
ROA % 4.94
NVS's ROA % is ranked higher than
56% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. NVS: 4.94 )
Ranked among companies with meaningful ROA % only.
NVS' s ROA % Range Over the Past 10 Years
Min: 4.94  Med: 8.59 Max: 16.19
Current: 4.94
4.94
16.19
ROC (Joel Greenblatt) % 49.37
NVS's ROC (Joel Greenblatt) % is ranked higher than
87% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. NVS: 49.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.78  Med: 59.62 Max: 69.75
Current: 49.37
43.78
69.75
3-Year Revenue Growth Rate 2.90
NVS's 3-Year Revenue Growth Rate is ranked lower than
59% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVS: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.9  Med: 2.5 Max: 12.3
Current: 2.9
-3.9
12.3
3-Year EBITDA Growth Rate -4.80
NVS's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 0.4 Max: 11.6
Current: -4.8
-7.7
11.6
3-Year EPS without NRI Growth Rate -4.80
NVS's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 3.2 Max: 82
Current: -4.8
-7.1
82
GuruFocus has detected 6 Warning Signs with Novartis AG NVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVS's 30-Y Financials

Financials (Next Earnings Date: 2018-01-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

NVS Guru Trades in Q4 2016

Chris Davis 257,670 sh (New)
Manning & Napier Advisors, Inc 5,554,008 sh (+48.02%)
John Rogers 15,402 sh (+10.69%)
Dodge & Cox 45,718,521 sh (+4.90%)
PRIMECAP Management 21,246,828 sh (+3.35%)
Ken Fisher 6,074,870 sh (+0.16%)
First Eagle Investment 12,848 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Sarah Ketterer 318,018 sh (-1.01%)
Tweedy Browne 216,590 sh (-1.60%)
Kahn Brothers 27,071 sh (-2.07%)
Mairs and Power 6,053 sh (-4.74%)
Mario Gabelli 5,870 sh (-6.30%)
Jim Simons 2,287,000 sh (-9.07%)
Murray Stahl 24,850 sh (-15.04%)
Eaton Vance Worldwide Health Sciences Fund 172,411 sh (-32.57%)
» More
Q1 2017

NVS Guru Trades in Q1 2017

Steven Cohen 670,600 sh (New)
Jerome Dodson 285,000 sh (New)
John Rogers 48,737 sh (+216.43%)
Chris Davis 298,710 sh (+15.93%)
Dodge & Cox 50,585,790 sh (+10.65%)
Jim Simons 2,458,498 sh (+7.50%)
Sarah Ketterer 338,149 sh (+6.33%)
Kahn Brothers 27,911 sh (+3.10%)
PRIMECAP Management 21,693,804 sh (+2.10%)
Ken Fisher 6,121,673 sh (+0.77%)
First Eagle Investment 12,848 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Murray Stahl 24,850 sh (unchged)
Mairs and Power 5,894 sh (-2.63%)
Mario Gabelli 5,620 sh (-4.26%)
Tweedy Browne 204,747 sh (-5.47%)
Manning & Napier Advisors, Inc 5,002,121 sh (-9.94%)
Eaton Vance Worldwide Health Sciences Fund 93,506 sh (-45.77%)
» More
Q2 2017

NVS Guru Trades in Q2 2017

Pioneer Investments 96,500 sh (New)
Chris Davis 352,820 sh (+18.11%)
Sarah Ketterer 369,006 sh (+9.13%)
Murray Stahl 27,040 sh (+8.81%)
Ken Fisher 6,505,935 sh (+6.28%)
John Rogers 49,665 sh (+1.90%)
PRIMECAP Management 22,094,224 sh (+1.85%)
Jerome Dodson 285,000 sh (unchged)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 50,143,509 sh (-0.87%)
Mario Gabelli 5,495 sh (-2.22%)
Tweedy Browne 196,422 sh (-4.07%)
Manning & Napier Advisors, Inc 4,767,723 sh (-4.69%)
Kahn Brothers 26,211 sh (-6.09%)
Mairs and Power 4,250 sh (-27.89%)
Jim Simons 1,474,500 sh (-40.02%)
Steven Cohen 115,900 sh (-82.72%)
» More
Q3 2017

NVS Guru Trades in Q3 2017

Pioneer Investments 317,300 sh (+228.81%)
John Rogers 57,697 sh (+16.17%)
Jerome Dodson 321,301 sh (+12.74%)
Ken Fisher 6,632,984 sh (+1.95%)
Tweedy Browne 196,952 sh (+0.27%)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Steven Cohen Sold Out
Kahn Brothers 26,144 sh (-0.26%)
PRIMECAP Management 21,964,764 sh (-0.59%)
Chris Davis 350,186 sh (-0.75%)
Mario Gabelli 5,395 sh (-1.82%)
Murray Stahl 26,540 sh (-1.85%)
Jim Simons 1,444,200 sh (-2.05%)
Manning & Napier Advisors, Inc 4,392,659 sh (-7.87%)
Dodge & Cox 44,643,925 sh (-10.97%)
Mairs and Power 3,750 sh (-11.76%)
Sarah Ketterer 310,514 sh (-15.85%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-09-30 Reduce -10.97%0.39%$81.97 - $86.23 $ 83.98-0%44,643,925
Ken Fisher 2017-09-30 Add 1.95%0.02%$81.97 - $86.23 $ 83.98-0%6,632,984
Chris Davis 2017-09-30 Reduce -0.75%$81.97 - $86.23 $ 83.98-0%350,186
Tweedy Browne 2017-09-30 Add 0.27%$81.97 - $86.23 $ 83.98-0%196,952
John Rogers 2017-09-30 Add 16.17%0.01%$81.97 - $86.23 $ 83.98-0%57,697
Kahn Brothers 2017-09-30 Reduce -0.26%$81.97 - $86.23 $ 83.98-0%26,144
Mario Gabelli 2017-09-30 Reduce -1.82%$81.97 - $86.23 $ 83.98-0%5,395
Dodge & Cox 2017-06-30 Reduce -0.87%0.03%$72.74 - $86.34 $ 83.986%50,143,509
Ken Fisher 2017-06-30 Add 6.28%0.05%$72.74 - $86.34 $ 83.986%6,505,935
Chris Davis 2017-06-30 Add 18.11%0.02%$72.74 - $86.34 $ 83.986%352,820
Tweedy Browne 2017-06-30 Reduce -4.07%0.02%$72.74 - $86.34 $ 83.986%196,422
John Rogers 2017-06-30 Add 1.90%$72.74 - $86.34 $ 83.986%49,665
Kahn Brothers 2017-06-30 Reduce -6.09%0.02%$72.74 - $86.34 $ 83.986%26,211
Mario Gabelli 2017-06-30 Reduce -2.22%$72.74 - $86.34 $ 83.986%5,495
Dodge & Cox 2017-03-31 Add 10.65%0.31%$70.03 - $78.17 $ 83.9813%50,585,790
Ken Fisher 2017-03-31 Add 0.77%0.01%$70.03 - $78.17 $ 83.9813%6,121,673
Chris Davis 2017-03-31 Add 15.93%0.01%$70.03 - $78.17 $ 83.9813%298,710
Tweedy Browne 2017-03-31 Reduce -5.47%0.03%$70.03 - $78.17 $ 83.9813%204,747
John Rogers 2017-03-31 Add 216.43%0.03%$70.03 - $78.17 $ 83.9813%48,737
Kahn Brothers 2017-03-31 Add 3.10%0.01%$70.03 - $78.17 $ 83.9813%27,911
Mario Gabelli 2017-03-31 Reduce -4.26%$70.03 - $78.17 $ 83.9813%5,620
Dodge & Cox 2016-12-31 Add 4.90%0.14%$67.59 - $79.13 $ 83.9816%45,718,521
Ken Fisher 2016-12-31 Add 0.16%$67.59 - $79.13 $ 83.9816%6,074,870
Chris Davis 2016-12-31 New Buy0.08%$67.59 - $79.13 $ 83.9816%257,670
Tweedy Browne 2016-12-31 Reduce -1.60%0.01%$67.59 - $79.13 $ 83.9816%216,590
Kahn Brothers 2016-12-31 Reduce -2.07%0.01%$67.59 - $79.13 $ 83.9816%27,071
John Rogers 2016-12-31 Add 10.69%$67.59 - $79.13 $ 83.9816%15,402
Mario Gabelli 2016-12-31 Reduce -6.30%$67.59 - $79.13 $ 83.9816%5,870
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:XSWX:ROG, NYSE:PFE, NYSE:MRK, NYSE:ABBV, XPAR:SAN, XTER:BAYN, NYSE:BMY, NYSE:LLY, LSE:GSK, LSE:AZN, TSE:4503, TSE:4519, TSE:4578, TSE:4568, TSE:4528, HKSE:01093, TSE:4151, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Headquarter Location:Switzerland
Novartis AG is a part of the healthcare industry. Its main activity is to research and develop healthcare products and pharmaceuticals such as oncology medicines, generic and biosimilar medicines and eye care devices.

Novartis develops and manufactures healthcare products within four main operating segments: branded drugs, generic pharmaceuticals, eye care products, and consumer products. The company sells its products globally with the U.S. representing close to a third of total sales.

Guru Investment Theses on Novartis AG

Jerome Dodson Comments on Novartis - Apr 26, 2017

With the market at all-time highs, it’s difficult to find undervalued stocks with attractive prospects. However, we uncovered a few that we believe are hidden gems. Our first new addition is Novartis (NYSE:NVS), the Swiss pharmaceutical giant. Management is focused on turning around Alcon, its leading eye-care franchise, whose sales have been soft the past few years. We recently met with Mike Ball, the CEO of Alcon, and we’re impressed with his vision to reinvigorate this great business. Meanwhile, investors are giving the company little credit for its enviable portfolio of innovative therapies that should drive revenue growth, including Entresto, an exciting new treatment that provides hope for chronic heart failure patients.

Jerome Dodson (Trades, Portfolio)'s first quarter 2017 Parnassus Funds commentary.

Check out Jerome Dodson latest stock trades

Top Ranked Articles about Novartis AG

Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Let’s Talk About CAR-T A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
For those interested in staying up to date with the latest developments in biotechnology it is impossible to overlook the developments of chimeric antigen receptor therapy (CAR-T) and the potential it holds for treating cancer. The most pivotal moment came on Aug. 30 when Novartis (NVS) announced approval for Kymriah™ (tisagenlecleucel) for treating children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Read more...
Novartis and the Future of Gene Therapy The company recently became the first to market a gene therapy for cancer
Gene therapy is now, finally, a new weapon in our arsenal against cancer partly thanks to, of all things, the HIV virus. The world’s first chimeric antigen receptor T-cell (CAR-T) treatment was approved by the Food and Drug Administration at the end of last month, a treatment developed by one Dr. Carl June at University of Pennsylvania in partnership with Novatris AG (NYSE:NVS). Read more...
Everybody Wins With GlaxoSmithKline's Latest Deal What the latest deal means for the cancer space as a whole
GlaxoSmithKline PLC (NYSE:GSK) just announced it has executed on an option that will see it license a technology developed, and proprietary to, by small-cap biotechnology stock Adaptimmune Therapeutics PLC (NASDAQ:ADAP). Read more...
John Rogers Continues to Buy Accenture, Novartis, Apache The guru purchased these stocks in the last 2 quarters
John Rogers (Trades, Portfolio) founded Ariel Investment LLC in 1983. In both the first and second quarters the guru bought shares in the following stocks: Read more...
Chris Davis Keeps Buying Intel, Ctrip.com, Novartis The guru bought these stocks in the last 2 quarters
Chris Davis (Trades, Portfolio) is the portfolio manager of Davis Financial Fund. In both the first and second quarters the guru bought shares in the following stocks: Read more...
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP The guru's largest 1st-quarter transactions
Dodge & Cox was founded in 1930 by Van Duyn Dodge and E. Morris Cox, and it manages a portfolio of 179 stocks. During the first quarter the guru traded shares in the following companies. Read more...

Ratios

vs
industry
vs
history
PE Ratio 30.92
NVS's PE Ratio is ranked lower than
60% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. NVS: 30.92 )
Ranked among companies with meaningful PE Ratio only.
NVS' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.91 Max: 31.27
Current: 30.92
5.7
31.27
Forward PE Ratio 15.67
NVS's Forward PE Ratio is ranked higher than
59% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. NVS: 15.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.92
NVS's PE Ratio without NRI is ranked lower than
60% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. NVS: 30.92 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.19 Max: 31.27
Current: 30.92
10.63
31.27
Price-to-Owner-Earnings 20.68
NVS's Price-to-Owner-Earnings is ranked higher than
72% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. NVS: 20.68 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 15.39 Max: 21.91
Current: 20.68
7.18
21.91
PB Ratio 2.90
NVS's PB Ratio is ranked lower than
51% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. NVS: 2.90 )
Ranked among companies with meaningful PB Ratio only.
NVS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.44 Max: 3.52
Current: 2.9
1.69
3.52
PS Ratio 4.08
NVS's PS Ratio is ranked lower than
60% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. NVS: 4.08 )
Ranked among companies with meaningful PS Ratio only.
NVS' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.03
Current: 4.08
1.89
5.03
Price-to-Free-Cash-Flow 20.86
NVS's Price-to-Free-Cash-Flow is ranked higher than
59% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. NVS: 20.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.04  Med: 16.96 Max: 26.65
Current: 20.86
7.04
26.65
Price-to-Operating-Cash-Flow 16.15
NVS's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. NVS: 16.15 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 13.14 Max: 19.28
Current: 16.15
5.75
19.28
EV-to-EBIT 26.45
NVS's EV-to-EBIT is ranked lower than
66% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. NVS: 26.45 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 27
Current: 26.45
8.5
27
EV-to-EBITDA 16.97
NVS's EV-to-EBITDA is ranked lower than
51% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. NVS: 16.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18.1
Current: 16.97
7.3
18.1
EV-to-Revenue 4.42
NVS's EV-to-Revenue is ranked lower than
61% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. NVS: 4.42 )
Ranked among companies with meaningful EV-to-Revenue only.
NVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.3 Max: 5.4
Current: 4.42
2.1
5.4
Shiller PE Ratio 17.42
NVS's Shiller PE Ratio is ranked higher than
83% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. NVS: 17.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.7  Med: 15.02 Max: 21.67
Current: 17.42
9.7
21.67
Current Ratio 1.01
NVS's Current Ratio is ranked lower than
89% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. NVS: 1.01 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.38 Max: 2.83
Current: 1.01
0.83
2.83
Quick Ratio 0.75
NVS's Quick Ratio is ranked lower than
88% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. NVS: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.12 Max: 2.48
Current: 0.75
0.59
2.48
Days Inventory 139.97
NVS's Days Inventory is ranked lower than
61% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. NVS: 139.97 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 139.97
117.82
183.45
Days Sales Outstanding 60.73
NVS's Days Sales Outstanding is ranked higher than
62% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. NVS: 60.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 60.73
56.31
70.59
Days Payable 97.16
NVS's Days Payable is ranked higher than
66% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. NVS: 97.16 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 97.16
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.23
NVS's Dividend Yield % is ranked higher than
89% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. NVS: 3.23 )
Ranked among companies with meaningful Dividend Yield % only.
NVS' s Dividend Yield % Range Over the Past 10 Years
Min: 1.53  Med: 3.43 Max: 5.11
Current: 3.23
1.53
5.11
Dividend Payout Ratio 0.99
NVS's Dividend Payout Ratio is ranked higher than
64% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVS: 0.99 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.99
Current: 0.99
0.4
0.99
3-Year Dividend Growth Rate 7.60
NVS's 3-Year Dividend Growth Rate is ranked higher than
51% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NVS: 7.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0.7  Med: 7.85 Max: 18.5
Current: 7.6
0.7
18.5
Forward Dividend Yield % 3.27
NVS's Forward Dividend Yield % is ranked higher than
84% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. NVS: 3.27 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.16
NVS's 5-Year Yield-on-Cost % is ranked higher than
87% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. NVS: 4.16 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.97  Med: 4.42 Max: 6.58
Current: 4.16
1.97
6.58
3-Year Average Share Buyback Ratio 0.70
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. NVS: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 29.47
NVS's Price-to-Tangible-Book is ranked lower than
96% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. NVS: 29.47 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 4.49 Max: 12455
Current: 29.47
2.68
12455
Price-to-Intrinsic-Value-Projected-FCF 1.36
NVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. NVS: 1.36 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.67  Med: 1.16 Max: 2.46
Current: 1.36
0.67
2.46
Price-to-Median-PS-Value 1.25
NVS's Price-to-Median-PS-Value is ranked lower than
66% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. NVS: 1.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.15 Max: 3.11
Current: 1.25
0.64
3.11
Price-to-Graham-Number 6.37
NVS's Price-to-Graham-Number is ranked lower than
92% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. NVS: 6.37 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 2.07 Max: 81.67
Current: 6.37
1.27
81.67
Earnings Yield (Greenblatt) % 3.75
NVS's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. NVS: 3.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 3.75
3.7
11.8
Forward Rate of Return (Yacktman) % 2.91
NVS's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. NVS: 2.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 12.45 Max: 42.2
Current: 2.91
1
42.2

More Statistics

Revenue (TTM) (Mil) $49,226.00
EPS (TTM) $ 2.74
Beta0.73
Short Percentage of Float0.00%
52-Week Range $66.93 - 86.90
Shares Outstanding (Mil)2,342.90 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,741 51,413 55,403
EPS ($) 4.78 5.24 5.87
EPS without NRI ($) 4.78 5.24 5.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.31%
Dividends per Share ($) 2.82 2.98 3.18

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}